SAN FRANCISCO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) is now grappling with a proposed class-action lawsuit alleging the company misled investors about the commercial readiness and demand for its critical “next generation” sleep apnea device, the Inspire V. The litigation zeroes in on the disparity between the company's confident assurances and the subsequent disastrous rollout that led to a dramatic stock crash. Prominent investor rights law firm Hagens Berman is inves ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. (INSP) for securities fraud, following a significant drop in stock price due to poor performance and misleading statements regarding the launch of its new sleep apnea device, Inspire V [1][3][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of shareholders who purchased Inspire common stock between August 6, 2024, and August 4, 2025, with a deadline for filing a lead plaintiff motion set for January 5, 2026 [1]. - The lawsuit alleges that the company made materially false and misleading statements and failed to disclose adverse facts about its business and operations during the class period [5]. Group 2: Company Performance - On August 4, 2025, Inspire disclosed that the launch of the Inspire V device was facing delays due to issues such as incomplete training for treatment centers, software update delays, and excess inventory leading to poor demand [3]. - The company reduced its 2025 earnings guidance by over 80%, from a range of $2.20 to $2.30 per share down to $0.40 to $0.50 per share [3]. Group 3: Stock Impact - Following the announcement of these issues, Inspire's stock price fell by $42.04, or 32.4%, closing at $87.91 per share on August 5, 2025, resulting in significant losses for investors [4].

Core Viewpoint - Inspire Medical Systems is facing legal scrutiny due to allegations of misleading investors regarding the demand and launch of its Inspire V device, leading to significant financial losses for investors [3][4]. Company Overview - Inspire Medical Systems, Inc. is under investigation by Faruqi & Faruqi, LLP for potential violations of federal securities laws [1][3]. - The company has been accused of making false statements about the market demand for its Inspire V device and the necessary steps taken for its launch [3]. Recent Developments - On August 4, 2025, Inspire Medical announced delays in the launch of the Inspire V device, citing that treatment centers had not completed required training and onboarding [4]. - The company also faced billing and reimbursement challenges, as necessary software updates for claims processing were not implemented until July 1, 2025 [4]. - Inspire Medical reported weak demand and excess inventory for the Inspire V device, leading to a drastic cut in its 2025 earnings guidance by over 80% [5]. Financial Impact - Following the announcement of setbacks, Inspire Medical's stock price plummeted by more than 32%, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, resulting in a loss of approximately $1.2 billion in market capitalization [5]. Legal Proceedings - A federal securities class action has been filed against Inspire Medical, with a deadline of January 5, 2026, for investors to seek the role of lead plaintiff [1][6]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [6].

Core Viewpoint - A class action securities lawsuit has been filed against Inspire Medical Systems, Inc. due to alleged securities fraud affecting investors between August 6, 2024, and August 4, 2025 [2][4]. Group 1: Lawsuit Details - The lawsuit claims that the launch of Inspire Medical's new product, Inspire V, was unsuccessful due to poor demand and excess inventory at treatment centers, contradicting the company's assurances of a successful launch [3]. - Defendants allegedly failed to complete essential tasks for the product launch, including training for treatment center customers, setting up IT systems, and ensuring proper Medicare reimbursement [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 5, 2026, to request appointment as lead plaintiff, although participation does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [5].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [2][4]. Group 1: Lawsuit Details - The lawsuit has been filed against Inspire Medical Systems and certain senior executives, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [4]. - Investors have until January 5, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Minnesota [4]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [5]. Group 3: Stock Performance and Issues - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," leading to a reduction in 2025 earnings per share guidance by over 80% [8]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025, following this announcement [9]. Group 4: Allegations of Mismanagement - The lawsuit alleges that Inspire failed to adequately prepare clinicians and payors for the rollout of Inspire V, resulting in significant delays and weak demand due to excess inventory of older devices [7][8].

Core Insights - U.S. stocks experienced a rally in Q3, supported by the Federal Reserve's interest rate cut and steady economic data, with the Russell Midcap® Growth Index increasing by 2.78% [3][17] - The Wasatch U.S. Select Fund underperformed, declining by -1.93%, primarily due to concentrated holdings in stocks that faced slower revenue growth [3][4][17] Fund Performance Analysis - The Fund's performance was negatively impacted by a few concentrated stock holdings that reported slower revenue growth, leading to significant declines in their stock prices [4][6] - The investment strategy focuses on high-quality, long-duration growth companies, which faced headwinds as low-quality stocks gained favor in the market [7] Key Detractors - BellRing Brands, Inc. (BRBR) was the largest detractor, with concerns over competition in the protein shake category; however, the long-term outlook remains positive due to category growth potential [8] - Shift4 Payments, Inc. (FOUR) faced stock price declines despite solid organic revenue growth, attributed to macroeconomic concerns and investor sentiment following its acquisition of Global Blue [9] - Inspire Medical Systems, Inc. (INSP) was sold during the quarter after management downgraded guidance due to delays in product rollout, raising execution concerns [10] Top Contributors - Medpace Holdings, Inc. (MEDP) was the top contributor, with strong revenue and earnings growth, raising full-year guidance despite a slowdown in biotech funding [11] - Fabrinet (FN) benefited from strong product adoption, particularly in data centers linked to AI, although the investment is not solely based on AI themes [12] - Nova Ltd. (NVMI) also contributed positively, with a strong track record in semiconductor manufacturing, benefiting from increasing complexity in the industry [13] Future Outlook - The Fund remains committed to its investment philosophy, focusing on high-quality growth companies despite recent underperformance [14] - The fundamentals of the companies within the Fund are encouraging, with strong earnings growth expected to drive return potential over a three- to five-year horizon [15]

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for misrepresentations regarding the market demand and launch of its sleep apnea device, Inspire V, during the specified Class Period from August 6, 2024, to August 4, 2025 [2][6]. Group 1: Lawsuit Details - The lawsuit claims that defendants made materially false and misleading statements about the demand for Inspire V and the necessary steps taken for its launch, leading to investor damages when the truth was revealed [6]. - Investors who purchased common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm for more information [4][7]. - A lead plaintiff must be appointed by January 5, 2026, to represent other class members in the litigation [2][4]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [5]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [5].

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Inspire Medical SystemsNovember 13, 2025 5:29 PM EST | Source: Faruqi & Faruqi LLPFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inspire Medical To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Inspire Medical between August 6, 2024 and August 4, 2025 and would like to discuss your legal rig ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud, following a significant drop in stock price due to poor performance and misleading statements regarding the launch of its new sleep apnea device, Inspire V [1][4][5]. Company Performance - On August 4, 2025, Inspire disclosed that the launch of the Inspire V device was facing delays due to issues such as incomplete training for treatment centers, software update delays, and excess inventory leading to poor demand [3]. - The company reduced its 2025 earnings guidance by over 80%, from a range of $2.20 to $2.30 per share down to $0.40 to $0.50 per share [3]. Stock Market Reaction - Following the announcement on August 5, 2025, Inspire's stock price fell by $42.04, or 32.4%, closing at $87.91 per share, which resulted in significant losses for investors [4]. Allegations in the Lawsuit - The lawsuit alleges that during the class period, the company made materially false and misleading statements and failed to disclose adverse facts about its business and operations, including poor demand for Inspire V and issues with training and IT systems [5]. - Specific failures included not completing necessary training for treatment centers, not updating critical software for claims processing, and not ensuring Medicare reimbursement was in place at launch [5].

New York, New York--(Newsfile Corp. - November 13, 2025) - If you suffered a loss on your Inspire Medical Systems, Inc. (NYSE: INSP) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/inspire-medical-systems-inc-lawsuit-submission-form?prid=177137&wire=5&utm_campaign=5or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareho ...